K6S fundamentals
An in-depth look to MIRA PHARMACEUTICALS INC operating, investing, and financing activities
K6S free cash flow for Q3 24 is -1.65 M EUR. For 2023, K6S free cash flow was -5.1 M EUR and operating cash flow was -5.1 M EUR.
Q1 '21
Q1 '22
Q2 '22
Q3 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
Q1 '21
Q1 '22
Q2 '22
Q3 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM